Cancer Platinum Resistance Detection and Sensitization Method

The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.

Attached files:
US 20110166095.jpg

Patents:
US 20,110,166,095

Inventor(s): LANCASTER JOHNATHAN M [US]; MARCHION DOUGLAS C [US]; CHEN DUNG-TSA [US]

Type of Offer: Licensing



Next Patent »
« More Biotech Patents

Share on      


CrowdSell Your Patent